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Abstract
Aims/hypothesis The aim of this work was to examine the progression to type 1 and type 2 diabetes after gestational diabetes
mellitus (GDM) in a 23 year follow-up study.
Methods We carried out a cohort study of 391 women with GDM diagnosed by an OGTT or the use of insulin treatment during
pregnancy, and 391 age- and parity-matched control participants, who delivered in 1984–1994 at the Oulu University Hospital,
Finland. Diagnostic cut-off levels for glucose were as follows: fasting, ≥4.8 mmol/l; 1 h, ≥10.0 mmol/l; and 2 h, ≥8.7 mmol/l.
Two follow-up questionnaires were sent (in 1995–1996 and 2012–2013) to assess the progression to type 1 and type 2 diabetes.
Mean follow-up time was 23.1 (range 18.7–28.8) years.
Results Type 1 diabetes developed (5.7%) during the first 7 years after GDMpregnancy and was predictable at a 2 h OGTT value
of 11.9 mmol/l during pregnancy (receiver operating characteristic analysis: AUC 0.91, sensitivity 76.5%, specificity 96.0%).
Type 2 diabetes increased linearly to 50.4% by the end of the follow-up period and was moderately predictable with fasting
glucose (AUC 0.69, sensitivity 63.5%, specificity 68.2%) at a level of 5.1 mmol/l (identical to the fasting glucose cut-off
recommended by the International Association of Diabetes and Pregnancy Study Groups [IADPSG) and WHO]).
Conclusions/interpretation All women with GDM should be intensively monitored for a decade, after which the risk for type 1
diabetes is minimal. However, the incidence of type 2 diabetes remains linear, and therefore individualised lifelong follow-up is
recommended.
Keywords GDM . Insulin . OGTT . Prediction . Type 1 diabetes . Type 2 diabetes
Anna-Maaria Auvinen and Kaisu Luiro contributed equally to this work.
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00125-020-05215-3) contains peer-reviewed but
unedited supplementary material, which is available to authorised users.
* Juha S. Tapanainen
juha.tapanainen@helsinki.fi
1 Department of Obstetrics and Gynecology, Oulu University
Hospital, Oulu, Finland
2 PEDEGO Research Unit, Medical Research Centre, University of
Oulu, Oulu, Finland
3 Department of Obstetrics and Gynecology, University of Helsinki
and Helsinki University Hospital, PO 140 (Haartmaninkatu 2E),
00029 Helsinki, Finland
4 Center for Life Course Health Research, University of Oulu,
Oulu, Finland
5 Unit of Primary Care, Oulu University Hospital, Oulu, Finland
6 Department of Obstetrics and Gynecology, Kuopio University
Hospital, Kuopio, Finland
7 Children’s Hospital, University of Helsinki and Helsinki University
Hospital, Helsinki, Finland
8 Research Program for Clinical andMolecularMetabolism, Faculty of
Medicine, University of Helsinki, Helsinki, Finland
9 Tampere Center for Child Health Research, Tampere University
Hospital, Tampere, Finland
https://doi.org/10.1007/s00125-020-05215-3
/ Published online: 29 July 2020
Diabetologia (2020) 63:2123–2128
Abbreviations
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Introduction
The prevalence of gestational diabetes mellitus (GDM) [1]
and type 2 diabetes [2] is increasing worldwide and studies
have shown that women with GDM are at high risk of devel-
oping diabetes later in life. However, the reported incidence of
type 2 diabetes after GDM varies considerably from 3% to
70% depending on the follow-up time and ethnicity [3–5].
The overall incidence of type 1 diabetes mellitus after GDM
is significantly lower, at 5–7% in Europe, but the risk
increases with the number of positive autoantibodies and the
duration of follow-up after pregnancy [6].
Insulin resistance increases during pregnancy because of
increasing weight and adiposity combined with reduced insu-
lin sensitivity by placental hormones. In relatively short
follow-up studies (up to 15 years), high glucose levels in an
OGTT, age, BMI, insulin treatment during pregnancy and a
single autoantibody positivity have been predictive factors of
later onset of diabetes [7–9].
We previously reported a prospective 6 year follow-up
study of women with GDM and healthy control counterparts,
showing that 4.6% of the GDM cohort developed type 1
diabetes and 5.3% developed type 2 diabetes, while none of
the control group became diabetic [6]. We report here the
results of the 23 year follow-up study of these women
regarding the progression to type 1 and type 2 diabetes after
GDM, including demographic, diagnostic and treatment data.
Methods
Study population and design The population and design of
this study has been described previously [6], and further infor-
mation can be found in the electronic supplementary material
(ESM)Methods. Briefly, this cohort study included 435 white
women with GDM and a singleton pregnancy. The control
cohort of 435 white women was pair-matched by age
(±2 years), parity and date of delivery (±2 days). Both cohorts
delivered at the Oulu University Hospital, Finland. Only
women with GDM diagnosed by oral glucose tolerance test
(OGTT) (n = 363) or who were treated with insulin (n = 28),
and their matched control counterparts (n = 391), were includ-
ed in further analysis. The cut-off values for the glucose
concentrations were set according to the recommendation of
the Finnish Diabetes Association: fasting, ≥4.8 mmol/l; 1 h,
≥10.0 mmol/l; and 2 h, ≥8.7 mmol/l. Any single abnormal
value in the OGTT was considered diagnostic for GDM.
Questionnaire-based follow-up An invitation to participate in
this study was sent in 1995–1996 (1–11 years after pregnancy)
along with the first follow-up questionnaire and an informed
consent form. The questionnaire included questions about
GDM treatment (diet or insulin), pre-pregnancy weight and
height, progression to diabetes, time of diagnosis and diabetes
medication.
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A second questionnaire was sent out in 2012–2013.
Thirteen women with GDM (3.3%) and six control partici-
pants (1.5%) had died. Finally, 297 women with GDM and
297 control participants (76.0%) took part in the study. The
mean follow-up period from delivery to the date of completing
the questionnaire was 23.1 (range 18.7–28.8) years in the
GDM cohort and 23.3 (range 18.9–30.1) years in the control
cohort.
Statistical analysis Comparisons of baseline demographic
characteristics between the groups were performed using
one-way ANOVA. Kaplan–Meier survival curves were used
to compare the development of type 1 or type 2 diabetes after
pregnancy. To find the best predictive model for progression
to type 1 and type 2 diabetes, sensitivity and specificity,
receiver operating characteristic (ROC) curves were
constructed with continuous glucose values. AUC was used
in the classification analysis. The analyses were performed
with IBM SPSS Statistics for Windows (versions 21 and 25,
IBM, Armonk, NY) and RStudio (Boston, MA) software. The
figures were produced using the ggplot2 (R package version
0.4.6., https://CRAN.R-project.org/package=survminer) and
Adobe Illustrator (Adobe Systems, San Jose, CA).
Results
At the end of the follow-up period, the mean ± SD age of
the GDM cohort was 54.7 ± 6.4 years, and that of the
control cohort was 55.3 ± 6.4 years. Body weight and
BMI were higher in the GDM group than the control
group, as expected (ESM Tables 1, 2). However, weight
gain and increase in BMI during pregnancy was higher in
the control group. The influence of age on disease
progression is depicted in ESM Fig. 1 and in ESM
Results.
During the follow-up study, 53.2% of women in the GDM
group developed diabetes (type 1, 5.7%; type 2, 50.4%) and
5.5% developed type 2 diabetes in the control group (Fig. 1).
No-one in the control group developed type 1 diabetes.
Incidence of type 2 diabetes increased linearly until the end
of the study, while all the participants who developed type 1
diabetes were diagnosed during the first 7 years after pregnan-
cy. Details of the OGTT measurements are shown in ESM
Table 3.
OGTT glucose levels in prediction of disease progression
Pathological glucose value at any of the three OGTT time
points was associated with a shorter time to progression to
type 1 or type 2 diabetes (ESMFig. 2).Moreover, three abnor-
mal glucose values in OGTT were most predictive of both
type 1 and type 2 diabetes occurrence (Fig. 2). Altogether,
60.9% of the womenwith abnormal fasting glucose developed
type 2 diabetes. In the ROC analyses with continuous glucose
values, the most predictive single OGTT value regarding type
1 diabetes was the 2 h glucose value (AUC 0.91, sensitivity
76.5%, specificity 96.0% at a glucose level of 11.9 mmol/l).
The most predictive OGTT value for type 2 diabetes was
fasting glucose (AUC 0.69, sensitivity 63.5%, specificity
68.2% at a glucose level of 5.1 mmol/l) (ESM Table 4).
To dissect undiagnosed diabetes in our GDM cohort, we
analysed a subgroup ‘diabetes in pregnancy’ comprising of
women with fasting glucose ≥7.0 mmol/l or 2 h glucose
≥11.1 mmol/l, according to the WHO criteria [10]. Forty-
eight (12.3%) women belonged to this subgroup based on
their OGTT. During the follow-up period, 13 (27%) women
in this subgroup developed type 1 diabetes and 22 (46%)
women developed type 2 diabetes.
Insulin treatment for GDM in prediction of disease progres-
sion Women who received insulin treatment for GDM had a
higher probability of subsequent diagnosis of both type 1 and
type 2 diabetes (ESM Fig. 3). Furthermore, the time to diabe-
tes diagnosis was longer in women without insulin treatment
for GDM. Conversely, only a few women (1.2%) without
insulin treatment developed type 1 diabetes. The sensitivity
of insulin treatment to predict type 1 diabetes was 90.5% and
specificity 64.7% (AUC 0.78) according to the ROC analyses;
sensitivity as regards predicting type 2 diabetes was 56.9%,
and specificity 74.6% (AUC 0.66) (ESM Table 4).
Discussion
This 23 year prospective cohort study demonstrated that after
GDM, 5.7% of women developed type 1 diabetes and approx-
imately 50% developed type 2 diabetes. Type 1 diabetes was
diagnosed less than a decade after the GDM, while the inci-
dence for type 2 diabetes remained linear until the end of the
study.
To our knowledge, this is one of the longest prospective
follow-up studies on women with GDM. The majority of the
diagnoses (92.8%) were made based on OGTT, albeit using
capillary glucose determinations. In addition, the participation
rate (76%) was remarkably high considering the long follow-
up period. The main weakness of the study is the self-reported
disease progression. HadOGTT been performed systematical-
ly as part of the follow-up, the incidence of type 2 diabetes
might have been higher in both cohorts, as the prevalence of
undiagnosed disease is reported to be as high as 20% in the
general population [11]. It is very unlikely that the participants
would have mixed up the type of diabetes that they have, as the
diagnosis, treatment and follow-up of type 1 diabetes takes
place in a specialised hospital setting while type 2 diabetes care
occurs at the health-centre level. However, it is worth noting that
the incidence of type 1 diabetes among young adults is higher in
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Finland than in other countries [12]. At the time of this study, a
risk-based screening strategy for GDM was used in Finland,
while nowadays nearly universal screening is recommended,
and this may have underestimated the incidence of GDM.
Few prior studies compared the predictive value of single
glucose levels or their combinations in OGTT regarding type
2 diabetes development. In the current study, 60.9% of the
women with abnormal fasting glucose developed type 2
diabetes. Consistent with our results, three other studies
reported that abnormal fasting glucose is the strongest
predictor of later type 2 diabetes [13]. Conflicting results have
also been reported, showing abnormal 1 h glucose or 2 h
glucose to be the strongest predictor of type 2 diabetes [14].
However, the glucose load in OGTT also varied from 50 g to
75 g or 100 g among studies. In our study, each OGTT time
point was independently predictive of type 2 diabetes, justify-
ing the inclusion of the 1 h test, which is omitted in some
countries. Remarkably, the identical cut-off for fasting glucose
(5.1mmol/l) that was associatedwith the future type 2 diabetes
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Fig. 2 Probability of remaining free from (a) type 1 diabetes and (b) type
2 diabetes according to the number of pathological glucose values in
OGTT during the GDM pregnancy. Logrank p < 0.001. Mean (95% CI)
type 1 diabetes-free survival time was as follows: one pathological value,
no occurrence of type 1 diabetes; two pathological values, 28.2 (27.5,
29.0) years; three pathological values, 21.4 (18.8, 24.0) years. Mean
(95% CI) type 2 diabetes-free survival time was as follows: one patho-
logical value, 25.0 (23.8, 26.1) years; two pathological values, 24.3 (22.9,
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Fig. 1 Probability of remaining free from (a) diabetes, (b) type 1 diabetes
or (c) type 2 diabetes among women with and without GDM. Logrank
p < 0.001 in all figure parts. Mean (95% CI) diabetes-free survival time in
women with vs without GDM was as follows: diabetes, 21.5 (20.5, 22.4)
years vs 29.6 (29.3, 29.9) years; type 1 diabetes, 26.7 (25.8, 27.5) years vs
no occurrence of type 1 diabetes; and type 2 diabetes, 22.6 (21.7, 23.5)
years vs 29.6 (29.3, 29.9) years
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maternal complications in the Hyperglycemia and Adverse
Pregnancy Outcomes (HAPO) study, from which the current
International Association of Diabetes and Pregnancy Study
Groups (IADPSG)/WHO diagnostic guidelines are derived
[10, 15, 16]. Therefore, the present study further validates
the use of the lower fasting glucose cut-offs for GDM
diagnosis.
When examining the predictive value of OGTT
glucose levels in terms of progression to type 1 diabe-
tes, the most predictive single OGTT time point for
later type 1 diabetes was the 2 h glucose concentration
with a cut-off of 11.9 mmol/l, which is higher than the
current diagnostic level for GDM (7.8–8.6 mmol/l). In
addition, most of the women (72.9%) who fulfilled the
WHO criteria for the ‘diabetes in pregnancy’ subgroup
were later diagnosed with diabetes.
In the present study, insulin treatment during pregnancy
was a strong predictor for both type 1 and type 2 diabetes,
which is in agreement with several earlier studies [5, 6, 12,
13]. Moreover, women who had received insulin treatment for
GDM developed diabetes earlier, and only a few women
(1.2%) without insulin treatment developed type 1 diabetes.
During the first 10 years of follow-up, the development of
type 2 diabetes was rare in women without insulin treatment
for GDM, but thereafter the disease progression curve was
almost linear and parallel to that of women on insulin for
GDM. This reflects the association of exogenous insulin treat-
ment with the severity of an impaired glucose tolerance, also
predictive of higher diabetes progression rate later in life. In
addition, being over 30 years of age at the time of GDM
increased the progression rate to type 2 diabetes. However,
this association disappeared when the glucose levels from
the OGTT were included in the same model, which suggests
that abnormal glucose concentrations may be more important
indicators of later type 2 diabetes.
In conclusion, women with GDM, especially those on insulin
treatment, should be carefully monitored for the first decade after
the pregnancy, after which the risk for type 1 diabetes becomes
negligible. However, the risk for type 2 diabetes remains and
warrants an individualised, lifelong follow-up.
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